HomeCompareBAX vs FANG

BAX vs FANG: Dividend Comparison 2026

BAX yields 2.28% · FANG yields 2.04%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FANG wins by $69.68M in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
FANG
FANG
● Live price
2.04%
Share price
$198.65
Annual div
$4.05
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.70M
Annual income
$63,694,114.45
Full FANG calculator →

Portfolio growth — BAX vs FANG

📍 FANG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXFANG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + FANG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
FANG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
FANG
Annual income on $10K today (after 15% tax)
$173.29/yr
After 10yr DRIP, annual income (after tax)
$54,139,997.28/yr
At 15% tax rate, FANG beats the other by $54,139,988.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + FANG for your $10,000?

BAX: 50%FANG: 50%
100% FANG50/50100% BAX
Portfolio after 10yr
$34.86M
Annual income
$31,847,062.36/yr
Blended yield
91.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FANG right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
FANG
Analyst Ratings
1
Strong
45
Buy
5
Hold
Consensus: Buy
Price Target
$182.64
-8.1% upside vs current
Range: $100.00 — $240.00
Altman Z
1.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
FANG buys
0
No recent congressional trades found for BAX or FANG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXFANG
Forward yield2.28%2.04%
Annual dividend / share$0.36$4.05
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%100%
Portfolio after 10y$20.6K$69.70M
Annual income after 10y$10.26$63,694,114.45
Total dividends collected$602.00$69.21M
Payment frequencyquarterlyquarterly
SectorHealthcareEnergy
Analyst consensusHoldBuy
Analyst price target$19.75$182.64

Year-by-year: BAX vs FANG ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrFANG PortfolioFANG Income/yrGap
1← crossover$10,866$166.33$11,108$407.75$242.00FANG
2$11,750$123.31$12,732$846.58$982.00FANG
3$12,664$90.97$15,437$1,813.77$2.8KFANG
4$13,617$66.89$20,628$4,110.50$7.0KFANG
5$14,619$49.07$32,339$10,266.86$17.7KFANG
6$15,679$35.94$64,688$30,085.07$49.0KFANG
7$16,802$26.30$181,701$112,484.96$164.9KFANG
8$17,998$19.23$784,997$590,576.84$767.0KFANG
9$19,272$14.05$5,609,019$4,769,072.49$5.59MFANG
10$20,631$10.26$69,695,765$63,694,114.45$69.68MFANG

BAX vs FANG: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

FANGEnergy

Diamondback Energy, Inc., an independent oil and natural gas company, focuses on the acquisition, development, exploration, and exploitation of unconventional and onshore oil and natural gas reserves in the Permian Basin in West Texas. It focuses on the development of the Spraberry and Wolfcamp formations of the Midland basin; and the Wolfcamp and Bone Spring formations of the Delaware basin, which are part of the Permian Basin in West Texas and New Mexico. As of December 31, 2021, the company's total acreage position was approximately 524,700 gross acres in the Permian Basin; and estimated proved oil and natural gas reserves were 1,788,991 thousand barrels of crude oil equivalent. It also held working interests in 5,289 gross producing wells, as well as royalty interests in 6,455 additional wells. In addition, the company owns mineral interests approximately 930,871 gross acres and 27,027 net royalty acres in the Permian Basin and Eagle Ford Shale; and owns, operates, develops, and acquires midstream infrastructure assets, including 866 miles of crude oil gathering pipelines, natural gas gathering pipelines, and an integrated water system in the Midland and Delaware Basins of the Permian Basin. Diamondback Energy, Inc. was founded in 2007 and is headquartered in Midland, Texas.

Full FANG Calculator →
📬

Get this BAX vs FANG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.